These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34758746)

  • 1. Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report.
    Lau KS; Cheung BM; Lam KO; Chan SY; Lam KM; Yeung CF; Hung IF; Kwong DL; Tong CC; Leung TW; Luk MY; Lee AW; Yuen KK; Lee VH
    BMC Infect Dis; 2021 Nov; 21(1):1148. PubMed ID: 34758746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laryngeal Tuberculosis in a Patient on Avelumab for Metastatic Nasopharyngeal Carcinoma.
    Song JS; Jeffery CC
    J Immunother; 2020 Sep; 43(7):222-223. PubMed ID: 32780576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
    Chen HW; Kuo YW; Chen CY; Chang CH; Wang SM; Chien YC; Lu WC; Chen JP; Chang CY; Wei YF; Chang SC; Shu CC; Wang JY; Liao WY; Wang HC; Yu CJ
    Oncologist; 2024 Apr; 29(4):e498-e506. PubMed ID: 38227604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan.
    Manako T; Yasumatsu R; Nakano T; Matsuo M; Takeuchi T; Taura M; Tamae A; Yamauchi M; Masuda M; Taguchi K; Nakagawa T
    In Vivo; 2023; 37(2):747-755. PubMed ID: 36881083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.
    Lin C; Xu G; Gao S; Feng T; Li S
    Front Immunol; 2023; 14():1162190. PubMed ID: 37304292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Tuberculosis Following Immune Checkpoint Inhibitor Treatment for Recurrent Maxillary Squamous Cell Carcinoma.
    Kikuta S; Abe Y; Shinozaki K; Seki N; Kusukawa J
    Cureus; 2024 Jan; 16(1):e53203. PubMed ID: 38425601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy.
    Murakami S; Usui R; Nakahara Y; Kondo T; Kato T; Saito H
    Intern Med; 2021 Jun; 60(11):1743-1746. PubMed ID: 33390489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
    J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature.
    Zaemes J; Kim C
    Eur J Cancer; 2020 Jun; 132():168-175. PubMed ID: 32375103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors.
    Im Y; Lee J; Kim SJ; Koh WJ; Jhun BW; Lee SH
    Respir Med; 2020 Jan; 161():105853. PubMed ID: 32056727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
    Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
    J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
    Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
    Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Shionoya Y; Hirohashi Y; Takahashi H; Hashimoto M; Nishiyama K; Takakuwa Y; Nakatsugawa M; Kubo T; Kanaseki T; Tsukahara T; Torigoe T
    Anticancer Res; 2021 Jul; 41(7):3699-3706. PubMed ID: 34230169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis.
    Nakahama K; Kaneda H; Ogawa K; Matsumoto Y; Tani Y; Suzumura T; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
    Intern Med; 2022; 61(7):1039-1042. PubMed ID: 35370247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Kim HW; Kim JS; Lee SH
    Lung Cancer; 2021 Aug; 158():107-114. PubMed ID: 34146757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
    Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.